<strike id="pf1jn"><dl id="pf1jn"><del id="pf1jn"></del></dl></strike>
<strike id="pf1jn"><dl id="pf1jn"><del id="pf1jn"></del></dl></strike><span id="pf1jn"></span>
<span id="pf1jn"><dl id="pf1jn"><ruby id="pf1jn"></ruby></dl></span>
<span id="pf1jn"></span>
<strike id="pf1jn"><ins id="pf1jn"><del id="pf1jn"></del></ins></strike>
<strike id="pf1jn"></strike><span id="pf1jn"><i id="pf1jn"><ruby id="pf1jn"></ruby></i></span>
<strike id="pf1jn"><video id="pf1jn"><ruby id="pf1jn"></ruby></video></strike>
<th id="pf1jn"><noframes id="pf1jn">
<strike id="pf1jn"><i id="pf1jn"><del id="pf1jn"></del></i></strike>
<strike id="pf1jn"><dl id="pf1jn"></dl></strike>
Active Pharmaceutical Ingredients
Product CAS NO. Therapeutic Category CHINA US EU JAPAN OTHERS
Aprepitant 170729-80-3 Oncology CEP CTD
Bisoprolol Fumarate 104344-23-2 Cardiovascular GMP CEP JDMF CTD
Brexpiprazole 913611-97-9 Neurology & Psychiatry TP
Dabigatran Etexilate Mesylate 872728-81-9 Cardiovascular Approved USDMF JDMF CTD
Dabigatran Etexilate Mesylate Pellet 872728-81-9 Cardiovascular Approved CTD
Ibandronate Sodium 138926-19-9 Oncology GMP TP
Lenvatinib Mesylate 417716-92-8 Oncology TP
Parecoxib Sodium 198470-85-8 Anesthetic & Analgesics GMP CTD
Rotigotine 99755-59-6 Neurology & Psychiatry CTD
Silodosin 160970-54-7 Urinary system JDMF CTD
Sodium Fusidate 751-94-0 Anti-inflammatory GMP CTD
Sugammadex Sodium 343306-79-6 Anesthetic & Analgesics Under Approval CTD
Ticagrelor 274693-27-5 Cardiovascular Under Approval USDMF CTD
Ubenimex 58970-76-6 Oncology GMP JDMF CTD

▲ CTD dossier under filling/preparation

According to laws and regulations of People's Republic of China, relevant information of Schedule II Controlled Substance APIs is not released here.

Disclaimer: The product that is still under patent protection can only be used in research and development, not for commercial purpose.